Related Experiment Videos
American Heart Association scientific sessions
1University of Heidelberg, Germany. bernhard.winkelmann@med.uni-heidelberg.de
Expert Opinion on Investigational Drugs
|April 23, 2004
Summary
The Valsartan in Acute Myocardial Infarction Trial (VALIANT) found valsartan and captopril equally effective for heart attack survivors. Combining them offered no extra benefit but increased side effects.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- Presents key findings from late-breaking clinical trials at the American Heart Association Annual Scientific Sessions.
- Focuses on major cardiovascular research impacting clinical practice.
Framework:
- The Valsartan in Acute Myocardial Infarction Trial (VALIANT) compared valsartan, captopril, and their combination in post-myocardial infarction patients.
- Evaluated clinical outcomes, efficacy, and safety profiles of these cardiovascular medications.
Implementation:
- VALIANT demonstrated equal efficacy between valsartan and captopril.
- The combination therapy showed no additional clinical benefit and a higher risk of adverse events.
Implications:
- VALIANT is a landmark study, being the first large trial to compare ARB/ACE inhibitor combination in acute myocardial infarction.
- Highlights the importance of individualized treatment strategies and risk-benefit assessments in cardiovascular care.